Tissue transglutaminase in fibrosis -more than an extracellular matrix cross-linker Tissue transglutaminase (TG2) is upregulated in the pathogenesis of a wide variety of chronic diseases. In this review, special emphasis will be placed on fundamental mechanisms underlying the critical role of TG2 in fibroproliferative disorders. TG2 is best known for its cross-linking capacities in the extracellular space but has many critical and multifaceted roles beyond protein cross-linking, which are driven by the conformation and specific localization of the molecule.
As extracellular cross-linker TG2 promotes fibrotic disease through the storage of latent transforming growth factor (TGF)-b1 in a stiffened extracellular matrix. As membrane-bound cell adhesion cofactor and signaling protein and intracellular crosslinker or G-protein, TG2 promotes fibrotic disease through cell survival and profibrotic pathway activation on a signaling, transcriptional, and translational level. Similarities between the roles that TG2 plays in scar tissue and in the tumor stroma suggest that a deeper understanding of key common pathways in disease pathogenesis and progression might lead to the identification of novel treatment targets and the development of new drugs and diagnostic methods.
Tissue transglutaminase (TG2), also named tTG, EC 2.3.2.13, is the most studied representative of a structurally and functionally related family of proteins of which nine members have been identified in humans [1, 2] . TG2 is best known for its catalytic transamidation activity, resulting in the Ca 2þ -dependent posttranslational formation of covalent isopeptide bonds between glutamine and lysine residues [1] . Beyond its catalytic core, TG2 consists of an N-terminal b-sandwich and two C-terminal b-barrel domains (Figure 1 , left) [3e5] . Far less understood are TG2s multiple functions at the cell membrane, in the cytoplasm, and in the cell nucleus, such as adhesion, migration, growth, proliferation, survival, apoptosis, differentiation, and phenotype modulation [6, 7] . TG2 is an integrin and syndecan-binding adhesion coreceptor for fibronectin (Fn) . Approximately 5e40% of b1 integrins are in complex with TG2 and almost all cell-membrane bound TG2 forms 1:1 complexes with integrins [8, 9] , which suggests a prominent role for TG2 at the cell membrane. While the focus is often on its cross-linking capacities in the extracellular space, TG2 is also active through nonenzymatic proteineprotein interactions in both the extra-and intracellular space as further highlighted below. The reader is also referred to the following comprehensive review [10] .
TG2 is upregulated in the pathogenesis of a wide variety of chronic diseases
In most cases, the pathophysiological significance of TG2-induced modifications remains unclear. However, it is well documented that TG2 is involved in the pathogenesis of a wide variety of diseases, most notably neoplastic and fibroproliferative, including most malignant cancers and pulmonary, kidney, and cardiac fibrosis [11e14]. TG2 expression is highly correlated with cancer cell survival, malignancy, metastasis, and treatment resistance [13, 15] . TG2 morphologically and functionally 'shapes' the tumor and scar tissue stroma through extracellular matrix (ECM) cross-linking and binding of transforming growth factor (TGF)-b1 to the ECM, thus priming TGF-b1, one of the most effective profibrotic stimuli, for release and activation [16, 17] . Also, through its cell attachment and signaling mediator functions and its intracellular signaling and crosslinking functions, TG2 can promote tumor cell survival and the development of fibrotic (scar) cell phenotypes [7,8,18e23] . Major attempts are thus underway to develop potent TG2 inhibitors.
Environmental sensing through major conformational TG2 changes
The biochemical functions of TG2 largely depend on its molecular conformation (Figure 1 ). Various environmental factors cause allosteric conformational changes and include extracellular, intracellular, and intranuclear Ca 2þ concentrations, guanosine diphosphate (GDP) and guanosine triphosphate (GTP) concentrations, and matrix metalloproteinase (MMP)-mediated release of membrane bound TG2 into the ECM [7, 9] . When bound to GTP or GDP, TG2 adopts a closed conformation with the two C-terminal b-barrel domains folded in and blocking substrate access to the catalytic site. However, with excess Ca 2þ levels, TG2s affinity for GDP and GTP is reduced, leading to a very large change in molecular shape presenting an open molecular conformation with an accessible active catalytic crosslinking site (Figure 1b) [3, 24] . Low Ca 2þ and high GDP/GTP concentrations in the cytoplasm cause TG2 to adopt a predominantly closed conformation inside the cell [25] . The conformation that TG2 adopts at the cell membrane is largely unknown. No structure has yet been solved of TG2 complexed to any binding partner even though Fn can bind to the open and closed conformations of TG2 [5] . Closed state cytosolic TG2 can bind to heparan sulfate epitopes on exosome membraneeassociated syndecan-4 molecules which have a high binding affinity for the closed conformation of TG2. Syndecan-4edependent translocation of TG2 from the cytoplasm to the extracellular space takes place by fusion of exosomes with the outer cell membrane [9,26e28] . This mechanism was identified in fibrotic kidney disease by Furini et al. [27] . Syndecan-4easso-ciated TG2 delivered to the cell surface can interact with integrins and fibronectin to form membrane-associated protein complexes exerting cell adhesion/receptor protein functions (Figures 2 and 3) [7, 29] . MMP2/9 activity can lead to syndecan-TG2 shedding from the cell surface (Figure 3) [72] . For information regarding further binding sites (a1b-adrenergic receptor, PLCd1, nuclear export signaling peptide), the reader is referred to the following references [70, 71] . and Robertson et al. [75] . Membrane associated functions of TG2 (lower left section of figure). TG2-integrin clusters, TG2-FN-integrin, and TG2-FN-integrin-syndecan-4 complexes are known to activate intracellular Src-FAK/p190RhoGAP/RhoA-ROCK signaling pathways [7, 8, 19, 29, 41] . RhoA/ROCK pathway activation induces the assembly of cytoplasmic monomeric G-actin into F-actin fibers and the formation of stress fibers. Changes in actin dynamics are monitored by MRTF-A, which binds to cytoplasmic G-actin but dissociates from F-actin. Upon actin fiber assembly, MRTF-A thus uncouples from G-actin and the released MRTF-A enters the nucleus. Alternatively, Rho-signaling and cytoskeletal stress drive the downregulation of YAP/TAZ phosphorylation and the subsequent nuclear translocation and activation of YAP/TAZ. Nuclear MRTF-A and YAP/TAZ both act as transcription cofactors that promote profibrotic gene expression [46, 47] . RGD-independent cell adhesion to Fn depends on Fn-TG2-syndecan-4 interaction and is mediated via cytoplasmic a5b1 integrin and syndecan-2 activation by Syndecan-4 activated PKCa [29] . Membrane-associated TG2 interacts with growth factor receptors (such as for PDGF, VEGF, FGF, and EGF) and stimulates cell survival signaling pathways (e.g. FAK, Src, Akt, etc.) by promoting GF-receptor binding and activation [7, 21] . Storage of latent TGF-b1 in the ECM and mechanoactivation of TGF-b1 (right section of figure): TGF-b1 is secreted by cells in complex with its latency associated propeptide (LAP), which associates with latent TGF-b1 binding protein (LTBP-1) [76] . LTBP-1 facilitates secretion of TGF-b1 [77] and TG2 cross-links LTBP-1 to Fn and fibrillin ECM fibers Ⓑ [16,34]. As such, a matrix reservoir of inactive TGF-b1 is formed which is bound to the LTBP-1 and ECM and therefore unable to bind with its high affinity cell membrane receptor to activate the downstream SMAD-mediated signaling cascade [34, 74] . Latent TGF-b1 can be activated through its release from the ECM-bound TGFb-LAP-LTBP-1 complex by proteolysis Ⓐ or integrin-mediated cellular contraction Ⓑ [33 -35] . The N-and C-terminal matrix binding sequences of LTBP-1 [78] and integrin-binding RGD sequence of LAP [79] are critical for the activation of TGF-b1. Cell membrane-associated integrins bind to the RGD sequence on LAP Ⓑ and can expose the ECM-bound LTBP-1 to cellular contractile forces. This is especially effective when the LTBP-1 is bound to a stiff, deformationresistant ECM that counters cell-applied forces [17, 33, 35, 36] . As such, TGF-b1 activation is thought to be facilitated by TG2 because TG2 cross-links LTBP to the ECM and can stiffen a compliant matrix via ECM cross-linking [37] . For a detailed review on TGF-b-LTBP interactions, we refer the reader to a recent comprehensive review published by Rifkin et al. [74] . ECM, extracellular matrix. (Figures 2 and 3 ) [33, 34] . ECM-bound TGF-b1 can be activated via mechanical release (Figure 3 ), which is especially effective when the LTBP-1 is bound to a stiff, deformation-resistant ECM that counters cell-applied forces [17, 33, 35, 36] . As such, TGF-b1 activation is thought to be facilitated by TG2 because TG2 cross-links LTBP to the ECM and can turn a compliant matrix into a stiffer matrix via cross-linking of various ECM components [37] . ECM prestress sensitizes latent TGF-b1 for activation [36] , which might explain increased TGF-b1 release from stiffened fibrotic tissues. Because increased and dysregulated expression, deposition, and cross-linking of ECM cause loss of vital organ function in fibrosis, TG2 and TGF-b1 are explored as targets for the treatment of fibrotic diseases.
Cell membrane: TG2 regulates cell adhesion and ligand affinity The importance of TG2 for cell adhesion is underlined by the discovery that TG2 was 1 of only 10 proteins that consistently appeared in seven integrin adhesome datasets analyzed by Horton et al. [45] .
Cell membrane: TG2 as signaling protein
Almost all cell membrane-associated TG2 is bound to integrins [8] , where TG2 dimers facilitate integrin cluster formation (Figure 3 ) [7, 19] . Further ECM components (e.g. Fn) and cell membrane protein receptors that bind next to fibronectin's RGD-specific integrin binding site (e.g. Syndecan-4, platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and epidermal growth factor (EGF) receptors) can be engaged by these TG2-integrin complexes to execute various cell adhesion (described previously) and signaling functions (Figure 3) [7,9,21,29]. TG2-integrin clusters, TG2-Fnintegrin, and TG2-Fn-integrin-syndecan-4 complexes are known to activate well-reviewed integrin signaling cascades, resulting in RhoA-Rho-associated protein kinase (ROCK) activation, actin filamentation, and downstream release and nuclear translocation of myocardin-related transcription factor A (MRTF-A) and yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) (Figure 3 ) [7, 8, 19, 46, 47] . Nuclear MRTF-A and YAP/TAZ both act as transcription cofactors that promote expression of profibrotic genes, including alpha smooth muscle actin (a-SMA), tenascin-C, and connective tissue growth factor (CTGF), which can influence the tumor stroma and cancer development and promote fibrotic disease [17, 48, 49] .
Inside the cell: enzymatic and nonenzymatic TG2 activity
With low Ca 2þ and high GDP/GTP concentrations in the cytoplasm, TG2 binds to and hydrolyzes GTP, assumes a closed conformation, and acts as a G protein. For example, TG2 binds to c-Src and PI3-kinase, facilitating c-Srcedependent phosphorylation of PI3-kinase which promotes cell survival [22] . Owing to fluctuations in Ca 2þ levels, cytoplasmic open conformation crosslinking activity of TG2 can also be observed with various specific and unspecific target proteins. For example, TG2 drives the constitutive activation of NFkB through its cross-linking activity, which leads to increased TGF-b1 expression (e.g. fibrotic diseases, cancer stroma), promotion of epithelial-mesenchymal transformation (increasing tumor malignancy), and cell survival [23, 49] . Similarly, RhoA cross-linking and activation leads to increased stress fiber formation [50] and certain translation regulatory proteins like YB-1 can be cross-linked in a state that drives increased a-SMA protein translation [20] . TG2 also regulates mitochondrial function and can initiate mitochondrial-driven apoptosis by cross-linking mitochondrial proteins in its open, catalytically active state [24, 51] . At the same time, TG2 cross-linking stabilizes the structure of dying cells, prevents leakage of proteolytic enzymes, and protects the environment of the cell from further damage [52] . Finally, high TG2 levels increase autophagy of the tumor suppressor p53, which can help tumor cells escape apoptosis [53] .
Nuclear TG2 has been shown to regulate gene expression via post-translational modification of transcriptional factors and related proteins, including Sp1, hypoxiainducible factor 1 and histones [54] . The G-protein function of cytosolic TG2 typically enhances cell survival [22] , whereas the transamidation activity of TG2 can lead to cell death or survival or even fibrotic changes [20,23,49e51,55] , depending on the target protein(s). Nuclear localization of TG2 is generally protective against cell death [56, 57] .
TG2 as major player in the development and maintenance of fibroproliferative diseases
Fibroproliferative disorders cause approximately 45% of the mortality in the developed world and appear in a wide spectrum from systemic to organ-specific fibrotic diseases. Besides increased mechanical tissue tension and the presence of certain ECM components, such as cellular fibronectin's ED-A domain, TGF-b1 is one of the most effective profibrotic stimuli that drive the transformation of fibroblasts into myofibroblasts [17] . Myofibroblasts are the key players within fibroproliferative disorders [17, 58] . They incorporate an excess of collagen and other fibrous proteins into the ECM while expressing strong contractile a-SMA positive stress fibers which contract the fibrotic matrix into a stiff, dysfunctional scar [17, 33, 48, 59] . Interestingly, TG2 and TGF-b1 reinforce each other in the progressive fibrotic and tumor stroma microenvironment [49] . As described in previous sections, TG2 facilitates the activation of TGF-b1 in the ECM [16], the activation of profibrotic signaling cascades downstream from TG2-b-integrine containing membrane signaling complexes [7] and the translation of a-SMA [20] . TGF-b1, on the other hand, promotes TG2 transcription [60, 61] , leading to selfamplification of TG2 and TGF-b1 in fibrotic tissues and explaining why both are upregulated in fibroproliferative disorders. The fact that TG2 knockout mice were protected against fibrosis [62, 63] and that TG2 inhibition in mouse models of fibrosis significantly reduced the fibrotic phenotype [11, 12, 64] further underlines the critical role that TG2 plays in the pathogenesis and maintenance of fibrosis [65] . The relative contributions of catalytic and noncatalytic TG2 functions to healthy and diseased microenvironments still remain unknown. Inhibition of TG2s catalytic function can reduce cardiac fibrosis in vivo [11, 64, 66] . Wang et al. and Shinde et al. suggested further reduction of fibrosis via noncatalytic TG2-mediated mechanisms: reduced externalization of TG2 as a result of decreased interaction of intracellular TG2 with exosome membranee associated syndecan-4, decreased TGF-b1einduced myofibroblast formation and reduced activation of fibrosis-associated genes [11, 64] .
Outlook: TG2 as common denominator in fibroproliferative and neoplastic diseases
The consensus in cancer research seems to mirror our aforementioned descriptions of the profibrotic functions of TG2. Extracellular TG2 in its open enzymatically active conformation promotes cancer cell malignancy through cross-linking of the tumor stroma [49, 55] . Intracellular closed conformation TG2 promotes cancer cell survival and malignancy through survival pathway and epithelial-to-mesenchymal transition (EMT) activation [22, 49] . Stabilizing the open state of TG2 inside the cell promotes cell death and inhibits the malignant phenotype of cancer cells, thus representing a promising new avenue in the treatment of cancer [24, 25] . Similarities between scar tissue and tumor stroma [67e69] suggest that the identification of key common pathways involved in the disease pathogenesis and progression might lead to the identification of novel treatment targets and the development of new drugs and diagnostic methods.
Beyond its role as ECM cross-linker, much future research is needed to understand the many roles of TG2, including cell adhesion stabilization and its nuclear functions. Also, translational research is required as only a few TG2 inhibitors are in clinical trials and none is available for clinical use [55] . The fibronectin ED-
